Medulloblastoma Recurrent

Oncology·MeSH: Medulloblastoma

Prevalence

5.0 / 100K

9 drugs in development·2 companies·3 clinical trials

Drug Pipeline by Phase

Phase 2(9)

Drug	Company
Celecoxib	Black Diamond Therapeutics, Inc. (BDTX)
Celecoxib	AIM ImmunoTech Inc. (AIM)
Cytarabine	AIM ImmunoTech Inc. (AIM)
Etoposide	AIM ImmunoTech Inc. (AIM)
etoposide phosphate	AIM ImmunoTech Inc. (AIM)
Fenofibric acid	AIM ImmunoTech Inc. (AIM)
Fenofibric acid	Black Diamond Therapeutics, Inc. (BDTX)
Thalidomide	Black Diamond Therapeutics, Inc. (BDTX)
Thalidomide	AIM ImmunoTech Inc. (AIM)

BioSniper tracks 9 drugs in development for Medulloblastoma Recurrent across 2 companies.

There are 3 clinical trials targeting Medulloblastoma Recurrent tracked by BioSniper.

The estimated prevalence of Medulloblastoma Recurrent is approximately 5.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.